key: cord-0052661-alx77fxy
authors: nan
title: Acknowledgement to referees
date: 2020-11-12
journal: Drugs Ther Perspect
DOI: 10.1007/s40267-020-00795-x
sha: 162e0d33f9db728e4a3e585509c74a39d470d30d
doc_id: 52661
cord_uid: alx77fxy

nan

Further, Drugs and Therapy Perspectives has published content in a timely manner, with an average time from submission to first decision of 20 days and from acceptance to online publication of 18 days.

In 2021, Drugs and Therapy Perspectives will continue to provide you with high-interest content relevant to real-world clinical settings. We thank you for your continued support.

With best wishes, Katherine A. Lyseng-Williamson, Editor-in-Chief Young A Heo, Associate Editor

Is Pakis tan prepa red to tackl e the coron aviru s epide mic? Saqlain M, Munir MM

• Preve nting COVID -19 in low-and middl e-incom e count ries Khadka S, Hashmi FK

• Is Pakis tan on track to have COVID -19 trans missi on and morta lity rates simil ar to those of Italy , Iran or the USA?

• Preve ntive measu res and manag ement of COVID -19 in pregn ancy Omer S

attit ude and preve ntive pract ices relat ed to COVID -19: a cross -secti onal study in two Pakis tani unive rsity popul ation s

• Prepa redne ss of pharm acist s to respo nd to the emerg ency of the COVID -19 pande mic in Brazi l: a compr ehens ive overv iew Parreiras Martins MA

• The chall engin g times and oppor tunit ies for pharm acovi gilan ce in Afric a durin g the COVID -19 pande mic OgarC

• Knowl edge and belie fs towar ds unive rsal safet y preca ution s durin g the coron aviru s disea se (COVID -19) pande mic among the India n publi c: a web-based cross -secti onal surve

• Withi n a large healt hcare syste m, the incid ence of posit ive COVID -19 resul ts and morta lity are lower in patie nts on chron ic hydro xychl oroqu ine thera py Sen S

• Revie w of evide nce on using ACEi and ARBs in patie nts with hyper tensi on and COVID -19

Curre nt pharm acy pract ices in low-and middl e-incom e count ries; recom menda tions in respo nse to the COVID -19 pande mic

• Parad igm shift of drug infor matio n cente rs durin g the COVID -19 pande mic Khatiwada AP

• Strat egies to conse rve salbu tamol press urize d meter ed-dose inhal er stock level s amid COVID -19 drug short age

• Pharm acoth erape utic consi derat ions for syste mic rheum atic disea ses amid the COVID -19 pande mic: more quest ions than answe rs Kow CS

• Shoul d commu nity pharm acies provi de COVID -19 scree ning servi ces?

• Self-medic ation durin g Covid -19 pande mic: chall enges and oppor tunit ies Malik M

The quality of published articles is also testament to the diligence of the peer reviewers, whose willingness to share their expertise ensures that the journal's content is held to the highest standard. We would like to acknowledge the following individuals who acted as reviewers for Drugs and Therapy Perspectives in the last 12 months: